Abstract
Diabetes is a common disorder, and many studies have shown that patients with diabetes mellitus have increased thrombotic complications including arterial and venous thromboses. Poorly controlled diabetes increases the risk of thrombosis. Recent reports have shown that a shortened activated partial thromboplastin time (APTT) and increased fibrinogen levels indicate a procoagulant condition. In this study, we evaluated the differences in global coagulation test values such as APTT, prothrombin time (PT), or fibrinogen levels, between well and poorly controlled diabetes. Three hundred forty-nine patients with type 2 diabetes mellitus were included. APTT, PT, fibrinogen, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), complete blood count (CBC), serum lipids, and HbA1c have been measured. Those with APTT <22 s and PT <10.5 s were identified. Furthermore, patients were divided into two groups based on HbA1c levels as follows: regulated diabetic group (HbA1c ≤7.0 %) and dysregulated diabetic group (HbA1c >7.0 %). No significant differences were found between the two groups in terms of shortened APTT (<22 s), PT (<10.5 s), or fibrinogen levels. Although inexpensive and widely available, global coagulation assays such as APTT, PT, and fibrinogen levels did not prove useful for evaluating hypercoagulable states in patients with diabetes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, et al. American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553–91.
Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, et al. Hyperglycemia: a prothrombotic factor? J Thromb Haemost. 2010;8:1663–9.
Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. Clinical and pathophysiological mechanisms and manifestations. Haemostasis. 1999;29:111–34.
Ng VL. Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med. 2009;29:253–63.
Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104:3631–4.
Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, et al. Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem. 2009;42:118–20.
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262:157–72.
Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med. 1999;159:2706–10.
Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, et al. Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420–5.
American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33:S11–61.
Barazzoni R, Zanetti M, Davanzo G, Kiwanuka E, Carraro P, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab. 2000;85:3121–5.
Schafer AI. The hypercoagulable states. Ann Intern Med. 1985;102:814–28.
Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat. 2001;15:44–54.
Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2 D-dimer and FVIII:C. Pathophys Haemost Thromb. 2002;32:137–42.
Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis. 2010;21:459–63.
Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis. 2010;21:152–7.
Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6(1):e16470.
Reverter JL, Reverter JC, Ta’ssies D, Rius F, Monteagudo J, et al. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol. 1997;56:93–9.
Festa A, D’Agostino R, Tracy R, Haffner S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes. 2002;51:1131–7.
Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672–6.
Van Wersch JW, Westerhuis LW, Venekamp WJ. Coagulation activation in diabetes mellitus. Haemostasis. 1990;20:263–9.
Missov R, Stolk R, van der Bom J, Hofman A, Bots ML, et al. Plasma fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care. 1996;19:157–9.
Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. SE Asian J Trop Med Public Health. 1993;1:263–6.
Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993;36:1119–25.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arpaci, D., Saglam, F., Ozdemir, D. et al. Does glycemic regulation affect hypercoagulable states in diabetic patients?. Int J Diabetes Dev Ctries 35 (Suppl 3), 512–515 (2015). https://doi.org/10.1007/s13410-015-0311-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13410-015-0311-6